NCT02182063View on ClinicalTrials.gov

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2007

Conditions
Prostatic Neoplasms
Interventions
DRUG

BIBF 1120 low dose

DRUG

BIBF 1120 high dose

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY